ATE522513T1 - N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung - Google Patents

N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung

Info

Publication number
ATE522513T1
ATE522513T1 AT05109059T AT05109059T ATE522513T1 AT E522513 T1 ATE522513 T1 AT E522513T1 AT 05109059 T AT05109059 T AT 05109059T AT 05109059 T AT05109059 T AT 05109059T AT E522513 T1 ATE522513 T1 AT E522513T1
Authority
AT
Austria
Prior art keywords
compound
methyl
production
active ingredient
phenylarylsulfonamide
Prior art date
Application number
AT05109059T
Other languages
English (en)
Inventor
Atsushi Naganawa
Tetsuji Saitoh
Kaoru Kobayashi
Takayuki Maruyama
Yoshihiko Nakai
Shinsuke Hashimoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE522513T1 publication Critical patent/ATE522513T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
AT05109059T 2001-03-12 2002-03-11 N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung ATE522513T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16

Publications (1)

Publication Number Publication Date
ATE522513T1 true ATE522513T1 (de) 2011-09-15

Family

ID=27346214

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05109059T ATE522513T1 (de) 2001-03-12 2002-03-11 N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
AT02705096T ATE362924T1 (de) 2001-03-12 2002-03-11 N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02705096T ATE362924T1 (de) 2001-03-12 2002-03-11 N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung

Country Status (24)

Country Link
US (3) US7235667B2 (de)
EP (2) EP1612208B1 (de)
JP (3) JP3555620B2 (de)
KR (1) KR100886854B1 (de)
CN (1) CN1294126C (de)
AT (2) ATE522513T1 (de)
AU (1) AU2002238855B2 (de)
BR (1) BR0208027A (de)
CA (1) CA2439604C (de)
CZ (1) CZ304035B6 (de)
DE (1) DE60220255T2 (de)
DK (2) DK1612208T3 (de)
ES (1) ES2286230T3 (de)
HU (1) HU230056B1 (de)
IL (2) IL157701A0 (de)
MX (1) MXPA03008134A (de)
NO (1) NO329682B1 (de)
NZ (1) NZ528120A (de)
PL (1) PL218750B1 (de)
PT (2) PT1612208E (de)
RU (1) RU2299202C2 (de)
TW (1) TWI317359B (de)
WO (1) WO2002072564A1 (de)
ZA (1) ZA200306884B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004022549A1 (ja) * 2002-09-09 2005-12-22 小野薬品工業株式会社 ４−メチル−１，３−チアゾール−２−イルスルホニルハライドの製造方法
PT1603893E (pt) * 2003-01-29 2008-08-21 Asterand Uk Ltd Antagonistas dos receptores ep4
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
JPWO2005000356A1 (ja) * 2003-06-27 2006-08-03 小野薬品工業株式会社 尿路疾患治療剤
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1767208A4 (de) * 2004-07-05 2007-12-05 Chugai Pharmaceutical Co Ltd Mittel zur behandlung von blasenüberaktivität
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
KR101492552B1 (ko) 2007-02-16 2015-02-12 오노 야꾸힝 고교 가부시키가이샤 요 배출 장애 치료제
US8048898B2 (en) * 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
MX2010014232A (es) * 2008-06-23 2011-03-25 Astellas Pharma Inc Compuesto de sulfamida o sal del mismo.
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
CN103209960A (zh) * 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
JP6103893B2 (ja) * 2012-11-15 2017-03-29 サントリー食品インターナショナル株式会社 コーヒーオイルの製造方法
DK3138633T3 (en) * 2014-04-30 2019-03-18 Ind Penalver Sl Programmable concentric head for applying liquid to lids with different designs
MY194015A (en) * 2015-11-13 2022-11-08 Daewoong Pharmaceutical Co Ltd Sodium channel blocker
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748534B2 (de) 1974-03-04 1982-10-16
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000069465A1 (fr) * 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif
AU6180600A (en) 1999-07-29 2001-02-19 Ono Pharmaceutical Co. Ltd. Sulfonamide derivatives and remedies for allodynia
WO2002072145A1 (fr) * 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif

Also Published As

Publication number Publication date
CN1509278A (zh) 2004-06-30
DE60220255D1 (de) 2007-07-05
CA2439604C (en) 2012-05-01
JPWO2002072564A1 (ja) 2004-07-02
PT1369419E (pt) 2007-08-16
NO329682B1 (no) 2010-11-29
HUP0400155A2 (hu) 2004-08-30
NO20034007D0 (no) 2003-09-10
US20060030713A1 (en) 2006-02-09
EP1612208B1 (de) 2011-08-31
ATE362924T1 (de) 2007-06-15
BR0208027A (pt) 2004-12-28
US7629369B2 (en) 2009-12-08
CZ304035B6 (cs) 2013-08-28
HU230056B1 (hu) 2015-06-29
JP2004149545A (ja) 2004-05-27
US20050124672A1 (en) 2005-06-09
JP2006028193A (ja) 2006-02-02
AU2002238855B2 (en) 2007-12-06
DE60220255T2 (de) 2008-01-17
EP1612208A2 (de) 2006-01-04
EP1612208A3 (de) 2006-12-06
NZ528120A (en) 2006-05-26
US7235667B2 (en) 2007-06-26
EP1369419A4 (de) 2005-03-16
CZ20032452A3 (cs) 2003-11-12
JP4432051B2 (ja) 2010-03-17
WO2002072564A1 (fr) 2002-09-19
KR100886854B1 (ko) 2009-03-05
CN1294126C (zh) 2007-01-10
RU2003127677A (ru) 2005-03-27
NO20034007L (no) 2003-11-12
DK1369419T3 (da) 2007-09-24
US8088802B2 (en) 2012-01-03
PL365100A1 (en) 2004-12-27
KR20030082978A (ko) 2003-10-23
PL218750B1 (pl) 2015-01-30
PT1612208E (pt) 2011-10-12
EP1369419B1 (de) 2007-05-23
US20100041708A1 (en) 2010-02-18
HUP0400155A3 (en) 2007-05-02
DK1612208T3 (da) 2011-12-12
JP3555620B2 (ja) 2004-08-18
MXPA03008134A (es) 2004-03-10
ES2286230T3 (es) 2007-12-01
IL157701A0 (en) 2004-03-28
IL157701A (en) 2010-06-30
JP3741120B2 (ja) 2006-02-01
RU2299202C2 (ru) 2007-05-20
EP1369419A1 (de) 2003-12-10
ZA200306884B (en) 2005-03-30
CA2439604A1 (en) 2002-09-19
TWI317359B (en) 2009-11-21

Similar Documents

Publication Publication Date Title
ATE522513T1 (de) N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
ATE479433T1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
MY143051A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
BR0014679A (pt) 2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação
ES2195943T3 (es) Compuestos heteroaromaticos biciclicos y triciclicos.
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
JP2022515293A (ja) クロモリンエステルおよびそれらの使用
WO2006125621A8 (en) Substituted piperidines as renin inhibitors
DE60039878D1 (de) XENON ALS NMDA-ANTOGONIST zur Neuroprotektion
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
PL370779A1 (en) Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
HUE027050T2 (en) Treatment of glomerulonephritis
JP2001508429A (ja) 選択プロスタグランジンエンドペルオキシドシンターゼ−２の阻害剤
EP1348698A4 (de) Substituierte carbonsäurederivate
Kostadinova et al. 4-aminopyridine–the new old drug for the treatment of neurodegenerative diseases
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
JPS58159489A (ja) ２，３−ジアリ−ル−５−ハロチオフエン化合物
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
Breining et al. Neuronal nicotinic acetylcholine receptor modulators: recent advances and therapeutic potential
KR100767508B1 (ko) 20-ｈｅｔｅ 생산 효소 저해제
WO2002044130A1 (fr) Dérivés d'acide carboxylique substitués
DE50006842D1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
CY1109278T1 (el) Νεες ινδενο[2,1α]ινδενες και ισοϊνδολ[2,1-α]ινδολες
RU96119347A (ru) 2-(4-метоксифенокси)-3-аминопиридин, его получение и применение в качестве противовоспалительного агента

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1612208

Country of ref document: EP